| Abstract | Boron neutron capture therapy (BNCT) is a binary cancer treatment modality where two different agents (B and thermal neutrons) have to be present to produce an effect. A dedicated trial design is necessary for early clinical trials. The concentration of B in tissues is an accepted surrogate to predict BNCT effects on tissues. Tissue, blood, and urines were sampled after infusion of two different boron carriers, namely BSH and BPA in the frame of the European Organisation for Research and Treatment of Cancer (EORTC) trial 11001. In this study, urine samples were used to identify protein profiles prior and after drug infusion during surgery. Here, an approach that is based on the mass spectrometry (MS)-based proteomic analysis of urine samples from head and neck squamous cell carcinoma (HNSCC) and thyroid cancer patients is presented. This method allowed the identification of several inflammation- and cancer-related proteins, which could serve as tumor biomarkers. In addition, changes in the urinary proteome during and after therapeutic interventions were detected. In particular, a reduction of three proteins that were involved in inflammation has been observed: Galectin-3 Binding Protein, CD44, and osteopontin. The present work represents a proof of principle to follow proteasome changes during complex treatments based on urine samples. |
| Text | 408179 2019 10.3390/molecules24040794 Scopus 2 s2.0 85062179902 BNCT; LC MS; MudPIT; boron; proteomics; squamous cell cancer of head and neck; thyroid cancer; urine Urinary proteomics profiles are useful for detection of cancer biomarkers and changes induced by therapeutic procedures Ferrari E.; Wittig A.; Basilico F.; Rossi R.; De Palma A.; Di Silvestre D.; Sauerwein W.A.G.; Mauri P.L. Proteomics and Metabolomics Unit, Institute for Biomedical Technologies ITB CNR , Segrate, MI, 20090, , Italy; Dept. of Radiotherapy and Radiation Oncology, University Hospital Jena, Jena, 07743, , Germany; NCTeam, Strahlenklinik, Universitatsklinikum Essen, Essen, 45122, , Germany; Istituto di Scienze della Vita, Scuola Superiore Sant Anna, Pisa, 56127, , Italy Boron neutron capture therapy BNCT is a binary cancer treatment modality where two different agents B and thermal neutrons have to be present to produce an effect. A dedicated trial design is necessary for early clinical trials. The concentration of B in tissues is an accepted surrogate to predict BNCT effects on tissues. Tissue, blood, and urines were sampled after infusion of two different boron carriers, namely BSH and BPA in the frame of the European Organisation for Research and Treatment of Cancer EORTC trial 11001. In this study, urine samples were used to identify protein profiles prior and after drug infusion during surgery. Here, an approach that is based on the mass spectrometry MS based proteomic analysis of urine samples from head and neck squamous cell carcinoma HNSCC and thyroid cancer patients is presented. This method allowed the identification of several inflammation and cancer related proteins, which could serve as tumor biomarkers. In addition, changes in the urinary proteome during and after therapeutic interventions were detected. In particular, a reduction of three proteins that were involved in inflammation has been observed Galectin 3 Binding Protein, CD44, and osteopontin. The present work represents a proof of principle to follow proteasome changes during complex treatments based on urine samples. 24 Published version https //www.mdpi.com/1420 3049/24/4/794 Molecules_24 4_24040794 Molecules_24_4_24040794.pdf Articolo in rivista Molecules/MDPI, Molecular Diversity Preservation International 1420 3049 Molecules Basel, Online Molecules Basel, Online Molecules Basel, Online Molecules. Basel, Online rossana.rossi ROSSI ROSSANA emanuele.ferrari FERRARI EMANUELE fabrizio.basilico BASILICO FABRIZIO antonella.depalma DE PALMA ANTONELLA dario.disilvestre DI SILVESTRE DARIO pietroluigi.mauri MAURI PIETRO LUIGI |
